KURA ONCOLOGY, INC. Increase (Decrease) in Accrued Liabilities
KURA ONCOLOGY, INC. (KURA) reported Increase (Decrease) in Accrued Liabilities of $8.90 thousand for the 85-month period ending 2014-12-31, per its 10-K filed 2015-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2015-02-27
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2014-12-31 was $5.44K.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2014-09-30 was $537.00, a 114.80% increase year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2014-06-30 was -$4.08K, a 426.00% decline year-over-year.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2014-03-31 was $1.50K.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2014 was $3.40K.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2012 was $0.00.
- KURA ONCOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2011 was $0.00.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 43 month | Increase (Decrease) in Accrued Liabilities 46 month | Increase (Decrease) in Accrued Liabilities 55 month | Increase (Decrease) in Accrued Liabilities 58 month | Increase (Decrease) in Accrued Liabilities 62 month | Increase (Decrease) in Accrued Liabilities 64 month | Increase (Decrease) in Accrued Liabilities 67 month | Increase (Decrease) in Accrued Liabilities 70 month | Increase (Decrease) in Accrued Liabilities 73 month | Increase (Decrease) in Accrued Liabilities 76 month | Increase (Decrease) in Accrued Liabilities 79 month | Increase (Decrease) in Accrued Liabilities 82 month | Increase (Decrease) in Accrued Liabilities 85 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-31 | $5.44K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $5.97K derived: sum of 2 quarters · filed 2015-02-27 | $1.90K derived: sum of 3 quarters · filed 2015-02-27 | $3.40K 10-K · filed 2015-02-27 | $8.90K 10-K · filed 2015-02-27 | ||||||||||||||
| 2014-09-30 | $537.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$3.54K derived: sum of 2 quarters · filed 2014-11-14 | -$2.04K 10-Q · filed 2014-11-14 | $3.46K 10-Q · filed 2014-11-14 | |||||||||||||||
| 2014-06-30 | -$4.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$2.58K 10-Q · filed 2014-08-14 | $2.92K 10-Q · filed 2014-08-14 | ||||||||||||||||
| 2014-03-31 | $1.50K 10-Q · filed 2014-05-15 | $7.00K 10-Q · filed 2014-05-15 | |||||||||||||||||
| 2013-12-31 | $5.50K 10-K · filed 2014-03-31 | ||||||||||||||||||
| 2013-09-30 | $250.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $1.50K derived: sum of 2 quarters · filed 2014-11-14 | -$2.50K 10-Q · filed 2014-11-14 | $1.50K derived: sum of 4 quarters · filed 2014-11-14 | $3.00K 10-Q · filed 2013-11-14 | ||||||||||||||
| 2013-06-30 | $1.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | -$2.75K 10-Q · filed 2014-08-14 | $1.25K derived: sum of 3 quarters · filed 2014-08-14 | $1.25K derived: sum of 4 quarters · filed 2014-08-14 | $2.75K 10-Q · filed 2013-08-14 | ||||||||||||||
| 2013-03-31 | -$4.00K 10-Q · filed 2014-05-15 | $0.00 derived: sum of 2 quarters · filed 2014-05-15 | $0.00 derived: sum of 3 quarters · filed 2014-05-15 | $0.00 derived: sum of 4 quarters · filed 2014-05-15 | $1.50K 10-Q · filed 2013-05-15 | ||||||||||||||
| 2012-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-28 | $4.00K derived: sum of 2 quarters · filed 2013-11-14 | $4.00K derived: sum of 3 quarters · filed 2013-11-14 | $0.00 10-K · filed 2013-03-28 | $5.50K 10-K · filed 2013-03-28 | ||||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | -$4.00K 10-Q · filed 2013-11-14 | -$162.00 derived: sum of 4 quarters · filed 2013-11-14 | $1.50K 10-Q · filed 2012-11-14 | ||||||||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | -$4.00K 10-Q · filed 2013-08-14 | -$162.00 derived: sum of 3 quarters · filed 2013-08-14 | -$75.00 derived: sum of 4 quarters · filed 2013-08-14 | $1.50K 10-Q · filed 2012-08-14 | ||||||||||||||
| 2012-03-31 | -$4.00K 10-Q · filed 2013-05-15 | -$162.00 derived: sum of 2 quarters · filed 2013-05-15 | -$75.00 derived: sum of 3 quarters · filed 2013-05-15 | ||||||||||||||||
| 2011-12-31 | $3.84K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-28 | $3.92K derived: sum of 2 quarters · filed 2013-03-28 | $0.00 10-K · filed 2013-03-28 | ||||||||||||||||
| 2011-09-30 | $87.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | -$3.84K 10-Q · filed 2012-11-14 | -$1.15K 10-Q · filed 2011-11-14 | $7.18K 10-Q · filed 2011-11-14 | |||||||||||||||
| 2011-06-30 | -$3.92K 10-Q · filed 2012-08-14 | -$2.14K 10-Q · filed 2011-08-15 | $6.18K 10-Q · filed 2011-08-15 | ||||||||||||||||
| 2010-09-30 | -$970.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$2.72K 10-Q · filed 2011-11-14 | |||||||||||||||||
| 2010-06-30 | -$1.75K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |